Search research articles
Contact Us
Filters
Showing results (31-40 of 48) with videos related to
Page
of 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 18, 2020
Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer
François Richard, Samira Majjaj, David Venet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 16, 2025
Unravelling the tumor microenvironment and PD-L1 expression across tissue type in high-grade serous ovarian cancer in the NeoPembrOV/GINECO phase II randomized trial
Laetitia Collet, Maude Ardin, David Venet, et al.
Nature Communications
|
November 26, 2024
Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications
Xiaoxiao Wang, David Venet, Frédéric Lifrange, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2021
Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial
David Venet, Mattia Rediti, Marion Maetens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 14, 2019
Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Françoise Rothé, Maria Joao Silva, David Venet, et al.
Nature Medicine
|
June 25, 2026
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER<sup>+</sup>HER2<sup>-</sup> breast cancer: a randomized phase 2 trial
Alex De Caluwé, Isabelle Desmoulins, Kim Cao, et al.
JAMA Oncology
|
March 28, 2024
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials
Aranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, et al.
Ebiomedicine
|
July 26, 2022
Timing evolution of lobular breast cancer through phylogenetic analysis
Danai Fimereli, David Venet, Mattia Rediti, et al.
JAMA Oncology
|
September 30, 2016
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Debora Fumagalli, David Venet, Michail Ignatiadis, et al.
Journal for Immunotherapy of Cancer
|
June 21, 2022
Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex
Dieke J van Rees, Panagiota Bouti, Bart Klein, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 48) with videos related to
Sort By:
Page
of 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 18, 2020
Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer
François Richard, Samira Majjaj, David Venet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 16, 2025
Unravelling the tumor microenvironment and PD-L1 expression across tissue type in high-grade serous ovarian cancer in the NeoPembrOV/GINECO phase II randomized trial
Laetitia Collet, Maude Ardin, David Venet, et al.
Nature Communications
|
November 26, 2024
Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications
Xiaoxiao Wang, David Venet, Frédéric Lifrange, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2021
Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial
David Venet, Mattia Rediti, Marion Maetens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 14, 2019
Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Françoise Rothé, Maria Joao Silva, David Venet, et al.
Nature Medicine
|
June 25, 2026
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER<sup>+</sup>HER2<sup>-</sup> breast cancer: a randomized phase 2 trial
Alex De Caluwé, Isabelle Desmoulins, Kim Cao, et al.
JAMA Oncology
|
March 28, 2024
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials
Aranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, et al.
Ebiomedicine
|
July 26, 2022
Timing evolution of lobular breast cancer through phylogenetic analysis
Danai Fimereli, David Venet, Mattia Rediti, et al.
JAMA Oncology
|
September 30, 2016
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Debora Fumagalli, David Venet, Michail Ignatiadis, et al.
Journal for Immunotherapy of Cancer
|
June 21, 2022
Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex
Dieke J van Rees, Panagiota Bouti, Bart Klein, et al.
Page
of 5